Product Images Losartan Potassium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 6 images provide visual information about the product associated with Losartan Potassium NDC 70518-1795 by Remedyrepack Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Remedy_Label - Remedy Label
This is a description of a medication called Losartan Potassium 50mg Tablet. The medication comes in a package of 30 tablets and should be stored at a temperature between 20-25°C. It is advised to keep the medication out of reach of children. The directions for use can be found in the package insert. The medication is packaged by RemedyRepack Inc. in Indiana, PA 15701.*
Chemical Structure - spl image1 structure1
Figure 1 - spl image2 figure1
This text presents some information about a clinical study comparing the effectiveness of Atenolol and Losartan Potassium in reducing the risk of a primary endpoint. The adjusted risk reduction achieved with Losartan Potassium was 13%, with a statistical significance of p=0.021. The study was conducted over 66 months, and the table shows the different study months.*
Figure 2 - spl image3 figure2
This appears to be a comparison study between two medications, Atenolol and Losartan Potassium. The study shows an adjusted risk reduction of 25% with a significance level of p=0.001. The chart displays the percentage of patients who experienced a fatal or non-fatal stroke at various study months.*
Figure 3 - spl image4 figure3
The given text describes the results of a clinical study on the efficacy of Losartan Potassium and Atenolol in preventing primary composite stroke in patients with certain demographic characteristics such as age, gender, race, hypertension, diabetes, and history of CVD. The study analyzes the number of events and hazard ratios of both drugs in different subgroups of patients. The text also includes a figure showing the comparison of primary endpoint events between Losartan Potassium and Atenolol in different demographic subgroups.*
Figure 4 - spl image5 figure4
This is a comparison of the effectiveness of Losartan Potassium versus Placebo in reducing events in patients over a period of 48 months. The table shows the percentage of patients who experienced an event at different intervals. The risk reduction associated with Losartan Potassium is stated to be 16.1%, with p=0.022. This could refer to a clinical trial or study evaluating the efficacy of Losartan Potassium as a treatment option.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.